FINANCE
-
I’m 75 and Retired With $900k. How Do I Avoid Running Out of Money?
Two 75-year-old retirees go over their finances to ensure their savings can support them for the rest of their lives. SmartAsset and Yahoo Finance LLC may earn commission or revenue through links in the content below. Ensuring that your retirement savings last the rest of your life often requires balancing income with expenses over your projected lifespan. But suppose you…
Read More » -
Intel’s Stock Just Did Something It Hasn’t Done Since 2022
The last couple of years have been terrific for semiconductor stocks. Well, most semiconductor stocks, that is. Since OpenAI introduced ChatGPT to the world on Nov. 30, 2022, shares of Nvidia and Advanced Micro Devices have risen by 721% and 83%, respectively. By contrast, shares of chip peer Intel (NASDAQ: INTC) have fallen by 25% during this time period. There’s…
Read More » -
Intel CEO Pat Gelsinger retires after tumultuous tenure leading the chip giant
Intel (INTC) announced Monday that CEO Pat Gelsinger retired effective Dec. 1 and stepped down from the company’s board of directors. He had led aggressive efforts to turn around the troubled US chipmaker for more than three years. Intel stock was up more than 3% on the news in early trading. A person familiar with the matter told Yahoo Finance…
Read More » -
Dow, S&P 500, Nasdaq rise with monthly wins in sight
Microsoft stock (MSFT) was down about 0.8% early Friday after news broke late Wednesday that the Federal Trade Commission has opened a broad antitrust probe into the tech giant. But at least one Wall Street analyst sees the news coming as no surprise and expects changes at the FTC under the Trump administration to make antitrust worries in the tech…
Read More » -
Best Buy broadly misses earnings estimates as consumers pull back on appliances, electronics
Even artificial intelligence couldn’t make up for flagging consumer demand at Best Buy (BBY). For the twelfth consecutive quarter, the retailer posted negative same-store sales growth, down 2.9% year over year versus estimates of down 0.92%. Net sales of $9.45 billion and adjusted earnings per share of $1.26 also missed expectation of $9.63 billion and $1.29 per share, respectively. CEO…
Read More » -
Here Are My Top Artificial Intelligence (AI) Stocks to Buy Right Now (Hint: Not Nvidia)
There are many ways to buy into the artificial intelligence (AI) frenzy. Many investors look to AI hardware designer Nvidia, making the former video gaming accelerator maven one of the most valuable companies in the world. Nvidia is a great company, but the stock may have soared too high, too fast. There are more reasonable AI ideas out there right…
Read More » -
US finalizes $1.5 billion chips award for GlobalFoundries to expand production
By David Shepardson WASHINGTON (Reuters) – The U.S. Commerce Department said Wednesday it has finalized a $1.5 billion government subsidy for GlobalFoundries to expand semiconductor production in Malta, New York and Vermont. The binding contract for New York-based GlobalFoundries, he world’s third-largest contract chipmaker, finalizes a preliminary award announced in February after the company said it was investing $13 billion…
Read More » -
1 Stock to Buy, 1 Stock to Sell This Week: Nvidia, Target
• Fed speakers and Nvidia earnings will be in focus this week. • Nvidia is a buy with another huge beat-and-raise quarter on deck. • Target is a sell amid declining sales, downbeat outlook expected. • Looking for more actionable trade ideas? Subscribe here for up 55% off as part of our Early Bird Black Friday sale! U.S. stocks finished…
Read More » -
Cava stock on a tear as fast-casual players continue to outperform the industry
Fast-casual chains continue to outpace the wider food industry in growth as value conscious diners demand affordable prices and experiences. Mediterranean chain Cava (CAVA) beat Wall Street estimates Tuesday afternoon, with same-store sales jumping 18.1%, compared to 12.39% expected. The stock vaulted over $172 per share — an all-time high — on Wednesday, before giving up the gains and closing…
Read More » -
AbbVie tumbles after new schizophrenia drug fails two trials
(Bloomberg) — AbbVie Inc. (ABBV) shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Most Read from Bloomberg The medicine, emraclidine, didn’t show a statistically significant improvement on a scale used for…
Read More »